Become a digitalPLUS subscriber. 99¢ for 4 weeks.
Business

Medifast adopts 'poison pill' plan to prevent takeover

Medifast Incorporated

Owings Mills-based Medifast has adopted a stockholder rights plan in an attempt to prevent a hostile takeover of the weight loss plan company.

Medifast said Thursday its board of directors adopted the one-year plan, a so-called "poison pill," "in response to the recent rapid accumulations of significant portions of Medifast's outstanding common stock" and "to guard against any attempt to gain control of Medifast without paying all stockholders a premium for that control."

A Massachusetts-based supply chain and logistics company, ModusLink Securities Corp., has bought nearly 10 percent of Medifast's shares since late July in transactions worth $35.4 million.

Medifast's plan, which issues one preferred stock purchase right for each outstanding share of Medifast common stock through Sept. 9, was not a response to a specific takeover bid or proposal, the company said.

The purchase rights become exercisable only if a person or group acquires ownership of 10 percent -- or 20 percent for institutional investors -- of Medifast without the board's approval, making it more difficult for an investor to gain control.

lorraine.mirabella@baltsun.com

Copyright © 2014, The Baltimore Sun
Related Content
Medifast Incorporated
  • Mass.-based company purchases 10% of Medifast shares
    Mass.-based company purchases 10% of Medifast shares

    A supply chain and logistics company based in Waltham, Mass., has purchased nearly 10 percent of the shares of Medifast, a weight loss program company based in Owings Mills, in a series of transactions since late July, according to a Securities and Exchange Commission filing.

  • Employers invest more in workplace wellness
    Employers invest more in workplace wellness

    Janis Smith feels a lot healthier — and more confident — since shedding 65 pounds in six months, and that has helped in her job leading employee training for 1st Mariner Bank.

Comments
Loading